Allergan Urgently Seeks FDA Guidance To Unblock Vraylar sNDA Review

In its initial assessment of Allergan's sNDA for Vraylar, the FDA has found the application - for treating negative symptoms associated with schizophrenia – wanting, and thus says it doesn't merit a full review.